SUPN
NASDAQ · Pharmaceuticals
Supernus Pharmaceuticals Inc
$45.14
+0.66 (+1.48%)
Financial Highlights (FY 2026)
Revenue
739.18M
Net Income
-39,635,328
Gross Margin
89.9%
Profit Margin
-5.4%
Rev Growth
+2.5%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 89.9% | 89.9% | 44.7% | 44.7% |
| Operating Margin | -8.7% | -7.8% | 26.9% | 29.3% |
| Profit Margin | -5.4% | -5.1% | 19.5% | 20.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 739.18M | 721.01M | 1.12B | 1.08B |
| Gross Profit | 664.45M | 648.12M | 502.48M | 484.03M |
| Operating Income | -64,013,189 | -56,195,737 | 302.53M | 316.79M |
| Net Income | -39,635,328 | -34,794,962 | 218.96M | 223.93M |
| Gross Margin | 89.9% | 89.9% | 44.7% | 44.7% |
| Operating Margin | -8.7% | -7.8% | 26.9% | 29.3% |
| Profit Margin | -5.4% | -5.1% | 19.5% | 20.7% |
| Rev Growth | +2.5% | +2.5% | +10.9% | -8.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 863.19M | 832.43M |
| Total Equity | — | — | 1.94B | 2.13B |
| D/E Ratio | — | — | 0.45 | 0.39 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 27.94M | 25.89M | 345.29M | 368.42M |
| Free Cash Flow | — | — | 147.80M | 181.78M |